Pricing Log in Create free account
Sunday 18 October 2026 Export FHTX’s income statement to Excel — free account

Foghorn Therapeutics Inc.

FHTX Healthcare Biotechnology

Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.

1.85 0.04 −2.12%
Market cap
$112.2M
P/E
0.0×
Fwd P/E
−3.7×
Dividend yield
—
F-score
2/9
Altman Z
−4.46
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 55.67%

Capital & Financial Ratios $m

Market Cap 112.24
Revenue 36.74
Net Income (64.58)
Free Cash Flow (84.31)
Net Debt (167.58)
Current Ratio 3.36 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (3.66) (negative: loss-making)
P/S ratio 3.56
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 23.04% (at or above 15%: strong)
Next Y EPS Growth 9.71%
Next Y revenue growth (7.11%) (below 0%: weak)
Next 5Y EPS Growth 14.13%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.5×, against a ten-year median of 4.7×; over the ten years it ranged from −5.6× in 2022 to 543× in 2021.
P/S against its own 10 years 0.30%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 234 244 160 168
Receivables — — — —
Inventory — — — —
Other — — — —
240 250 163 170
2023 2024 2025 Q'26
Payables 6 4 4 3
ST’ Debt — — — —
Other — — — —
58 67 60 51

Compound Annual Growth %

10y 5y 3y
Sales — 135.14% 17.14%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 3 16 — — —
’25 6 8 8 9 31
’24 5 7 8 3 23
’23 5 6 17 6 34
’22 4 4 7 4 19
’21 0 0 0 1 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (25) (18) — — —
’25 (24) (21) (19) (22) (86)
’24 (29) (26) (21) (25) (100)
’23 (31) (32) (27) (28) (118)
’22 272 (29) (20) (29) 194
’21 (23) (18) (21) 12 (50)
’20 (11) (13) 3 (11) (31)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (25) (18) — — —
’25 (24) (21) (19) (22) (86)
’24 (29) (26) (21) (25) (101)
’23 (32) (33) (27) (28) (119)
’22 271 (29) (20) (29) 192
’21 (25) (20) (21) 12 (54)
’20 (12) (15) (3) (18) (47)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.29) (0.10) — — —
’25 (0.30) (0.28) (0.25) (0.34) (1.18)
’24 (0.59) (0.45) (0.31) (0.30) (1.58)
’23 (0.73) (0.70) (0.34) (0.57) (2.34)
’22 (0.65) (0.66) (0.62) (0.69) (2.62)
’21 (0.62) (0.63) (0.71) (0.77) (2.73)
’20 (2.71) (2.90) (3.12) 2.50 (6.23)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 14.03 8.01 5.32 2.84 2.70 2.95

Analyst estimates 2026–2028

Powerpack
High — — — — 28.27 25.10 24.34 9.97 10.25 6.79
People
People Employees — — — 85 95 119 161 116 112 106
Revenue/emp, $m — — — 0.00 0.00 0.01 0.12 0.29 0.20 0.29
Income, $m
Income, $m Revenue — — — — 0 1 19 34 23 31
Gross margin, % — — 0.00 0.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT — — (26) (51) (69) (101) (109) (94) (87) (74)
EBT margin, % — — 0.00 0.00 (16,000.00) (7,681.58) (566.27) (275.80) (383.24) (240.33)
Net income — 0 (26) (51) (69) (101) (109) (98) (87) (74)
Depreciation — — 0 1 1 3 2 1 (1) 1
Per share, $
Per share, $ Revenue — — 0.00 0.00 0.04 0.04 0.46 0.81 0.41 0.49
Earnings — — (0.72) (12.20) (6.23) (2.73) (2.62) (2.34) (1.58) (1.18)
Cash flow — — (0.62) (11.05) (2.83) (1.35) 4.66 (2.81) (1.83) (1.37)
Capex — — 0.00 (0.23) (1.44) (0.09) (0.03) (0.03) (0.02) 0.00
Free cash flow — — (0.62) (11.28) (4.27) (1.44) 4.63 (2.84) (1.85) (1.37)
Book value — — (1.07) (0.35) 13.23 2.61 0.00 (1.84) (0.83) (1.72)
Shares, m — — 37 4 11 37 42 42 55 63
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — — 0.00 644.51 14.06 7.93 11.46 11.00
P/B — — — — 1.53 8.78 2,413.79 0.00 0.00 0.00
EV/Sales — — — — 0.00 542.63 (2.89) 1.66 1.56 6.47
EV/FCF — — — — (1.22) (13.36) (0.29) (0.47) (0.35) (2.32)
Cash, $m
Cash, $m Operating cash flow — — (23) (46) (31) (50) 194 (118) (100) (86)
Capex — — (2) (1) (16) (3) (1) (1) (1) 0
Free cash flow — — (23) (47) (47) (54) 192 (119) (101) (86)
Balance, $m
Balance, $m Working capital — — 37 4 172 411 296 182 183 103
Total debt — — 78 11 20 51 46 — — —
Net debt — — 38 (5) (166) (154) (346) (234) (244) (160)
Shareholders’ equity — — (39) (1) 146 97 0 (77) (46) (108)
Returns, %
Returns, % ROA — — (122.33) (156.35) (49.51) (26.13) (23.55) (28.50) (30.40) (30.82)
ROIC — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE — — 41.38 80.33 (236.54) (83.37) (224.54) 255.39 141.17 96.45
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Foghorn Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NERV Minerva Neurosciences, Inc $115.6M — (loss-making) — (loss-making) — n/m −553.48% (below 0%: shrinking) 0.00% 0.00% Compare
ARMP Armata Pharmaceuticals, Inc. $114.9M — (loss-making) — (loss-making) +15.72% (above 0%: growing) n/m −17.98% (below 0%: shrinking) 100.00% (410.84%) Compare
ENGN enGene Therapeutics Inc $114.6M — (loss-making) — — n/m +28.07% (above 0%: growing) — 0.00% Compare
SEER Seer, Inc. $113.0M — (loss-making) — (loss-making) −23.43% (below 0%: shrinking) n/m +36.73% (above 0%: growing) 48.55% (542.91%) Compare
FHTX Foghorn Therapeutics Inc. $112.2M — (loss-making) — (loss-making) +112.68% (above 0%: growing) n/m +14.88% (above 0%: growing) 100.00% (54.78%)
GNLX Genelux Corporation $112.2M — (loss-making) — (loss-making) — n/m −11.18% (below 0%: shrinking) 100.00% 0.00% Compare
LENZ LENZ Therapeutics, Inc. $112.2M — (loss-making) — (loss-making) +9.72% (above 0%: growing) n/m −229.66% (below 0%: shrinking) 94.90% (622.89%) Compare
TNXP Tonix Pharmaceuticals Holding Corp. $110.1M — (loss-making) — (loss-making) +577.88% (above 0%: growing) n/m −178.84% (below 0%: shrinking) 94.81% (314.05%) Compare
VTVT vTv Therapeutics Inc. $109.1M — (loss-making) — (loss-making) +409,222.22% (above 0%: growing) n/m −124.59% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $112.6M — — +15.72% — −71.28% 94.90% (157.02%)

All 614 Biotechnology stocks →

Foghorn Therapeutics Inc. (FHTX) key facts

  • Strength: Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024.
  • Foghorn Therapeutics Inc. (FHTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, FHTX traded at $1.85, a market capitalization of $112.2 million.
  • Return on equity was 96.5% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −4.46 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Foghorn Therapeutics Inc. (FHTX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/FHTX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com